<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21916">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02153112</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-202</org_study_id>
    <secondary_id>2014-000778-20</secondary_id>
    <secondary_id>U1111-1154-9733</secondary_id>
    <nct_id>NCT02153112</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide, With and Without Monophosphoryl Lipid A Adjuvant in Children, Toddlers, and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the optimal formulation of the norovirus vaccine from
      different concentrations of virus-like particles (VLP) combined with aluminum hydroxide with
      and without MPL adjuvant (3-O-desacyl-4'-monophosphoryl lipid A) for further development in
      children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like
      particle (VLP) vaccine with aluminum hydroxide adjuvanted with or without monophosphoryl
      lipid A (MPL). The norovirus vaccine is being tested to assess different formulations of the
      vaccine that will then be further developed. This study will look at the number of
      antibodies to norovirus formed in children, toddlers and infants who are administered
      different formulations of the norovirus vaccine.

      The study will enroll approximately 1210 participants. Participants will be randomly
      assigned (by chance) to one of eleven treatment groups—which will remain undisclosed to the
      participant and study doctor during the study (unless there is an urgent medical need).

      All participants in Cohort 1 will be vaccinated on Day 1 and Day 29 of the study, and all
      participants in Cohort 2 will be vaccinated on Day 1, Day 56, and Day 112. All treatment
      groups in Cohort 1 will receive either one dose of the norovirus vaccine, or two doses. One
      treatment group in Cohort 2 will receive 2 doses of the norovirus vaccine, and the other
      group will receive 3. In order to keep the treatment undisclosed to the participant and the
      doctor in Cohort 1, those randomized to the one-dose groups will receive the norovirus
      vaccine on Day 1, followed by a dose of placebo vaccine on Day 29. In order to keep the
      treatment arms undisclosed to the participant and the doctor in Cohort 2, those randomized
      to the two-dose groups will receive the norovirus vaccine on Day 1 and Day 56, followed by a
      dose of placebo vaccine on Day 112. Placebo vaccine is saline solution. Participants will be
      asked to record any symptoms that may be related to the vaccine or the injection site in a
      diary card for 7 days after each vaccination.

      This multi-center trial will be conducted in Finland, Panama, and Colombia. The overall time
      to participate in this study is up to 393 days for participants in Cohort 1 and up to 477
      Days for participants in Cohort 2. Participants in Cohort 1 will make 7 visits to the
      clinic, and participants in Cohort 2 will make 11 visits to the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of Participants with a Seroresponse (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroresponse defined as 4-fold rise or greater at Day 57 (Cohort 1) and Day 140 (Cohort 2) in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Solicited Local Adverse Events (AEs) at Injection Site</measure>
    <time_frame>Days 1 through 8 after each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 8 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Solicited Systemic Adverse Events (AEs)</measure>
    <time_frame>Through Day 8 after each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Systemic AEs are defined as headache, fatigue, myalgia, arthralgia, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 to &lt;9 years; and irritability/fussiness, drowsiness, loss of appetite, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 weeks to &lt;6 years on the day of vaccination and daily through Day 8 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature Through Day 8 after each Vaccination</measure>
    <time_frame>Post-vaccination approximately 30 minutes and 6 hours later, then daily through Day 8</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Body temperature measurement will be performed using the thermometer provided by the site through Day 8 after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Unsolicited Adverse Events (AEs)</measure>
    <time_frame>For 28 days after each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Unsolicited AEs are any local or systemic AEs, as defined by this study, that are not solicited.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Cohort 1: Day 1 up to Day 393; Cohort 2: Day 1 up to Day 477</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroresponse defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroresponse defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study</measure>
    <time_frame>Cohort 1: Day 1 up to Day 393; Cohort 2: Day 1 up to Day 477</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Cohort 1: Day 1 up to Day 393; Cohort 2: Day 1 up to Day 477</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AESIs are local or systemic AEs that are predefined in this study and are not solicited.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">1210</enrollment>
  <condition>Norovirus</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 6 to &lt;9 years of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 6 to &lt;9 years of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 3 to &lt;6 years of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 3 to &lt;6 years of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers 1 to &lt;3 years of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers 1 to &lt;3 years of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants 6 to &lt;12 months of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants 6 to &lt;12 months of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants aged 6 weeks to &lt;6 months of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1 and Day 56, followed by placebo saline solution, IM, on Day 112.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants aged 6 weeks to &lt;6 months of age will receive one dose of 1 of the 11 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, Day 56 and Day 112.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/15) - MPL (50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 50 µg monophosphoryl lipid A (MLP) for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/50) - MPL (50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 50 µg monophosphoryl lipid A (MLP) for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (50/50) - MPL (50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 50 µg monophosphoryl lipid A (MLP) for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/15) - MPL (15)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 15 µg monophosphoryl lipid A (MLP) for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/50) - MPL (15)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 15 µg monophosphoryl lipid A (MLP) for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (50/50) - MPL (15)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide adjuvanted with 15 µg monophosphoryl lipid A (MLP) for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/15)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (50/50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (50/150)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/50) - Al(OH)3 (167)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 167 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 3 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo saline solution</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 4: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 2: 2 Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female participants aged between 6 weeks and less than 9 years at the time
             of enrollment.

          2. Are in good health at the time of entry into the trial as determined by medical
             history, physical examination (including vital signs) and clinical judgment of the
             investigator.

          3. Participants legally acceptable representative signs and dates a written, informed
             consent form (ICF) and any required privacy authorization prior to the initiation of
             any trial procedures, after the nature of the trial has been explained according to
             local regulatory requirements. An assent will also be obtained according to
             age-appropriate country-specific regulations.

          4. Participants who can comply with trial procedures and are available for the duration
             of the trial.

        Exclusion Criteria:

          1. Participants with a clinically significant active infection (as assessed by the
             investigator) or body temperature 38.0°C (100.4°F) or higher within 3 days of the
             intended date of vaccination.

          2. Have received antipyretic/analgesic medications within 24 hours prior to the intended
             vaccine administration.

          3. Known hypersensitivity or allergy to investigational vaccine (including excipients of
             the investigational vaccines).

          4. Participants with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may interfere with the ability to participate in the
             trial.

          5. Has a history of any progressive or severe neurologic disorder, seizure disorder, or
             neuroinflammatory disease (eg, Guillain-Barré syndrome).

          6. Known or suspected impairment/alteration of immune function, including the following:

               1. Children &lt;18 months of age with history of repeated episodes of acute otitis
                  media (AOM) in the first 6 months of life (AOM defined as a bulging tympanic
                  membrane) and not to be confused with otitis media with effusion (OME).

               2. Chronic use of oral steroids (equivalent to 20 mg/day prednisone for ≥12
                  weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1 (use
                  of inhaled, intranasal, or topical corticosteroids is allowed).

               3. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2
                  mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1.

               4. Receipt of immunostimulants within 60 days prior to Day 1.

               5. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation,
                  blood products, and/or plasma derivatives within 3 months prior to Day 1 or
                  planned during the full length of the trial.

               6. Receipt of immunosuppressive therapy within 6 months prior to Day 1.

               7. Human immunodeficiency virus (HIV) infection or HIV-related disease.

               8. Chronic Hepatitis B or C infection.

               9. Heritable immunodeficiency.

          7. Abnormalities of splenic or thymic function.

          8. Has a known bleeding diathesis or any condition that may be associated with a
             prolonged bleeding time.

          9. Has any serious chronic or progressive disease according to judgment of the
             investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic
             disease).

         10. Is participating in any clinical trial with another investigational product 30 days
             prior to first trial visit or intent to participate in another clinical trial at any
             time during the conduct of this trial.

         11. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days
             (for live vaccines) prior to enrollment in this trial.

         12. Are first degree relatives of individuals involved in trial conduct.

         13. Has a history of autoimmune disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>800-778-2860</phone>
    <email>medicalinformation@tpna.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Monophosphoryl lipid A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
